



**FOR MORE INFORMATION:**

**Company Contact:**

Jacqueline Lemke  
President & CEO and CFO  
Phone: 765.497.5829  
[jlemke@BASinc.com](mailto:jlemke@BASinc.com)

**Agency Contact:**

Neil Berkman  
Berkman Associates  
Phone: 310.477.3118  
[info@berkmanassociates.com](mailto:info@berkmanassociates.com)

## **BASi Files Amended Form 10-K and 10-Q with the SEC**

WEST LAFAYETTE, IN -- October 11, 2013 -- **Bioanalytical Systems, Inc. (NASDAQ:BASI)** announced today that it has filed amended quarterly and annual reports with the SEC, including Form 10-K/A for the fiscal years ended September 30, 2011 and 2012, Form 10-Q/A for the three months ended December 31, 2011 and 2012, and Form 10-Q/A for the three and six months ended March 31, 2012 and 2013.

The Company currently expects to file with the SEC its Form 10-Q for the three and nine months ended June 30, 2013 by October 18, 2013.

### **About Bioanalytical Systems, Inc.**

BASi is a pharmaceutical development company providing contract research services and monitoring instruments to the world's leading drug development companies and medical research organizations. The company focuses on developing innovative services and products that increase efficiency and reduce the cost of taking a new drug to market. Visit [www.BASinc.com](http://www.BASinc.com) for more about BASi.

*This release contains forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry standards and regulatory standards, and various market and operating risks detailed in the company's filings with the Securities and Exchange Commission.*